BIOMAT Database Logo BIOMAT Database Logo

Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration. 2013

Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli

BACKGROUND Src tyrosine kinase activates inducible nitric oxide synthase (iNOS) and, in turn, nitric oxide production as a means to transduce cell migration. Src tyrosine kinase plays a key proximal role to control α9β1 signaling. Our recent studies have clearly demonstrated the role of α9β1 integrin in matrix metalloproteinase-9 (MMP-9) and/or urokinase plasminogen activator receptor (uPAR)-mediated glioma cell migration. In the present study, we evaluated the involvement of α9β1 integrin-iNOS pathway in MMP-9- and/or uPAR-mediated glioma cell migration. METHODS MMP-9 and uPAR shRNAs and overexpressing plasmids were used to downregulate and upregulate these molecules, respectively in U251 glioma cells and 5310 glioma xenograft cells. The effect of treatments on migration and invasion potential of these glioma cells were assessed by spheroid migration, wound healing, and Matrigel invasion assays. In order to attain the other objectives we also performed immunocytochemical, immunohistochemical, RT-PCR, Western blot and fluorescence-activated cell sorting (FACS) analysis. RESULTS Immunohistochemical analysis revealed the prominent association of iNOS with glioblastoma multiforme (GBM). Immunofluorescence analysis showed prominent expression of iNOS in glioma cells. MMP-9 and/or uPAR knockdown by respective shRNAs reduced iNOS expression in these glioma cells. RT-PCR analysis revealed elevated iNOS mRNA expression in either MMP-9 or uPAR overexpressed glioma cells. The migration potential of MMP-9- and/or uPAR-overexpressed U251 glioma cells was significantly inhibited after treatment with L-NAME, an inhibitor of iNOS. Similarly, a significant inhibition of the invasion potential of the control or MMP-9/uPAR-overexpressed glioma cells was noticed after L-NAME treatment. A prominent reduction of iNOS expression was observed in the tumor regions of nude mice brains, which were injected with 5310 glioma cells, after MMP-9 and/or uPAR knockdown. Protein expressions of cSrc, phosphoSrc and p130Cas were reduced with simultaneous knockdown of both MMP-9 and uPAR. CONCLUSIONS Taken together, our results from the present and earlier studies clearly demonstrate that α9β1 integrin-mediated cell migration utilizes the iNOS pathway, and inhibition of the migratory potential of glioma cells by simultaneous knockdown of MMP-9 and uPAR could be attributed to the reduced α9β1 integrin and iNOS levels.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016023 Integrins A family of transmembrane glycoproteins (MEMBRANE GLYCOPROTEINS) consisting of noncovalent heterodimers. They interact with a wide variety of ligands including EXTRACELLULAR MATRIX PROTEINS; COMPLEMENT, and other cells, while their intracellular domains interact with the CYTOSKELETON. The integrins consist of at least three identified families: the cytoadhesin receptors (RECEPTORS, CYTOADHESIN), the leukocyte adhesion receptors (RECEPTORS, LEUKOCYTE ADHESION), and the VERY LATE ANTIGEN RECEPTORS. Each family contains a common beta-subunit (INTEGRIN BETA CHAINS) combined with one or more distinct alpha-subunits (INTEGRIN ALPHA CHAINS). These receptors participate in cell-matrix and cell-cell adhesion in many physiologically important processes, including embryological development; HEMOSTASIS; THROMBOSIS; WOUND HEALING; immune and nonimmune defense mechanisms; and oncogenic transformation. Integrin

Related Publications

Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.
July 2010, Neurochemical research,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins.
May 2003, Annals of vascular surgery,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity.
January 2008, Molecular and cellular neurosciences,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
January 2017, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
May 2003, Cancer research,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells.
September 2010, Molecular cancer therapeutics,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2.
November 2014, Biochimica et biophysica acta,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
April 2005, Clinica chimica acta; international journal of clinical chemistry,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion.
July 2010, Molecular and cellular biochemistry,
Thompson Zhuang, and Bharath Chelluboina, and Shivani Ponnala, and Kiran Kumar Velpula, and Azeem A Rehman, and Chandramu Chetty, and Eleonora Zakharian, and Jasti S Rao, and Krishna Kumar Veeravalli
The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines.
January 2012, Molekuliarnaia biologiia,
Copied contents to your clipboard!